Company Overview
- Website
- kiromic.com
- Phone
- (832) 968-4888(844) 539-2873
- Employees
- 46
- Founded in
- 2012
- Industry
- BioTech/Drugs
- NAICS Codes
-
54 - Professional, Scientific, and Technical Services541 - Professional, Scientific, and Technical Services5417 - Scientific Research and Development Services54171 - Research and Development in the Physical, Engineering, and Life Sciences541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- SIC Codes
-
87 - Engineering, Accounting, Research, Management, and Related Services873 - Research, Development, and Testing Services
Financials & Stats
Revenue
$8B
Total Funding Amount
$15M
Recent News & Media
Kiromic BioPharma ($KRBPQ) Is Paying a $2.3M Settlement to Investors — Here’s How to Get Your Share
- Jul 4, 2025
- tradingview.com
KRBP INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed
- Jun 30, 2025
- accessnewswire.com
Houston-based Kiromic BioPharma finds buyer for assets after filing Chapter 7
- Apr 7, 2025
- bizjournals.com
Kiromic Biopharma files for Chapter 7 bankruptcy
- Mar 21, 2025
- investing.com
Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms
- Mar 18, 2025
- endpoints.news
Kiromic furloughs 'substantially all' workers amid cash crunch, leaving 31 staff without pay
- Mar 18, 2025
- fiercebiotech.com
Who is Kiromic
Kiromic BioPharma is a clinical-stage, fully integrated biotherapeutics company located in Houston, Texas. With 46 employees, Kiromic BioPharma is dedicated to developing and commercializing cell therapies focused on immuno-oncology. The company's innovative approach leverages the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic BioPharma utilizes its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine, streamlining the drug development process. Their multi-indication allogeneic cell therapy platform aims to revolutionize cancer treatment by targeting solid tumors with precision. Kiromic's strength lies in its unique, proprietary, end-to-end bioinformatic, AI targeting, and manufacturing technologies. Their commitment to cutting-edge technologies, combined with their expertise in immuno-oncology, positions Kiromic as a leader in the field of cellular therapies. Learn more about Kiromic BioPharma's groundbreaking work at www.kiromic.com. Connect with them on Twitter and LinkedIn to stay updated on their advancements.